Oncobit

Executive Summary

Oncobit is a Swiss MedTech company spun out from the University of Zurich in 2018, specializing in high-precision blood-based assays for personalized cancer care. The company's core technology enables close monitoring of circulating tumor DNA (ctDNA) to guide therapy decisions, aiming to improve patient outcomes by detecting minimal residual disease and early recurrence. Oncobit’s assays are designed to be highly sensitive and specific, leveraging proprietary methods to analyze ctDNA from standard blood draws. This non-invasive approach offers a significant advantage over traditional tissue biopsies, allowing for repeated sampling and real-time tracking of tumor dynamics. By enabling optimal therapy selection and timely adjustments, Oncobit plans to reduce ineffective treatments and enhance survival rates. The company operates in the rapidly growing liquid biopsy market, which is expected to expand as ctDNA analysis becomes a standard tool in oncology. As a privately held entity, Oncobit is currently focused on clinical validation and commercialization of its first assays, targeting partnerships with pharmaceutical companies and healthcare providers. While still in early stages, the technology holds strong potential to address key challenges in cancer management, particularly in monitoring treatment response and detecting resistance. The company’s success will depend on robust clinical data, regulatory approvals, and strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Publication of key clinical validation study for ctDNA monitoring assay70% success
• Q4 2026Series A or Series B funding round to support commercial launch60% success
• Q1 2027Strategic partnership with major pharmaceutical company for co-development40% success